08:00 , Nov 17, 2008 |  BC Week In Review  |  Company News

Antyra, Novo Nordisk deal

Antyra (formerly DGI Biotechnologies Inc.) received exclusive, worldwide rights from Novo Nordisk to develop and commercialize insulin-like growth factor (IGF) antagonists. Antyra plans to begin Phase I testing of ANT-429 to treat cancer after it...